Investigational drug · Phase 2
MR001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pancreatic Ductal Adenocarcinoma (PDAC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "MR001"
First trial start
2025
Dec 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MR001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Ductal Adenocarcinoma (PDAC)
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "MR001" as an intervention, largest first.
Shenzhen Majory Biotechnology Co., Ltd.Industry
NCT07235202 · 45 participants (planned) · Start Dec 24, 2025 · Primary completion Jun 22, 2028
Drug: MR001; Irinotecan Liposome Injection combined with 5-FU/LV and 2 more · For: Pancreatic Ductal Adenocarcinoma (PDAC)
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 18 sites in all
Shenzhen Majory Biotechnology Co., Ltd.Industry
NCT07208149 · 42 participants (planned) · Start Jan 29, 2026 · Primary completion Sep 1, 2028
Drug: MR001 Bispecific Antibody for Injection · For: Triple-Negative Breast Cancer (TNBC)
Sites: Beijing, China; Hubei, China; Hunan, China
- First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid TumorsStatus unknown
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
NCT06134531 · 31 participants (planned) · Start Nov 2023 · Primary completion Jul 2026
Drug: MR001 · For: Advanced Solid Tumors
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Feasibility, validation and application of digital tools for remote monitoring in neuromuscular diseases: the DT4RD protocol.
Hogrel JY, Santmarty P, Decostre V, et al. · BMJ Open 2026
- Outcomes and Health Economics of Stroke using Rhythmic Auditory Stimulation (OrcHESTRAS): a protocol for a pragmatic, decentralized, longitudinal, multi-phase, withdrawal with randomized re-treatment trial of MR-001 in chronic stroke.
Taylor SR, Awad LN, Carlowicz CA, et al. · Trials 2026
- Systematic referral to palliative care in patients attending dedicated emergency units from French comprehensive anticancer centres: the prospective multicentre randomised comparative clinical trial PALLU.
Chvetzoff G, Anota A, Perrier L, et al. · BMJ Open 2025
- Evaluation of probiotic characteristics and whole genome analysis of Pediococcus pentosaceus MR001 for use as probiotic bacteria in shrimp aquaculture.
Wanna W, Surachat K, Kaitimonchai P, et al. · Sci Rep 2021
Also in development for Pancreatic Ductal Adenocarcinoma (PDAC)
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- [18F]FAPI-74 PETPhase 33 trials
SOFIE · Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- Precemtabart tocentecanPrecem-TcT, M9140Phase 32 trials
EMD Serono Research & Development Institute, Inc. · Metastatic Colorectal Cancer, Solid Tumors, Gastric Cancer
- VS-7375Phase 24 trials
Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- BT5528nuzefatide pevedotinPhase 23 trials
BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.